Reimbursement Policy for Sparsentan/Sparsentan

Sparsentan is a new type of dual endothelin and angiotensin receptor antagonist, mainly used to treat primary IgA nephropathy (IgAN). This disease is a common glomerular disease characterized by IgA deposition in the renal tubules, leading to progressive deterioration of kidney function. High levels of proteinuria are an obvious symptom of IgAN patients and are usually closely related to further damage to renal function. Therefore, controlling proteinuria has become one of the key goals in treating IgAN.

Sparsentan effectively reduces the amount of protein excretion in the urine through its unique mechanism of action, thereby mitigating the risk of disease progression. Studies have shown that sparsentane can significantly improve patients' urinary protein/creatinine ratio (UPCR) and has demonstrated good safety and tolerability in clinical trials. This makes the application of sparsentan in IgAN patients of high clinical value, especially for those patients whose urinary protein excretion exceeds 1.5g/g, its efficacy is more obvious.

In terms of reimbursement policy, sparsentane, as a new drug, usually needs to go through certain review procedures before it can be included in the scope of medical insurance reimbursement. In the United States, after sparsentane received accelerated approval from the FDA, many insurance companies began to evaluate its clinical effectiveness and cost-effectiveness to decide whether to include it in the medical insurance payment catalog. Although specific reimbursement policies may vary by region and insurance plan, under normal circumstances, insurance companies will provide a certain degree of reimbursement support for IgAN patients who have been diagnosed by a doctor and meet the conditions for use.

It is worth noting that before receiving sparsentane treatment, patients should communicate with their attending physician in detail to understand the drug’s indications, potential side effects, and related costs. At the same time, doctors can assist patients in applying for drug reimbursement to ensure that patients can reduce their financial burden and successfully receive treatment.

Reference materials:https://ir.travere.com/news-releases/news-release-details/travere-therapeutics-announces-licensing-agreement-renalys